- Home
- CRNX vs FOLD Comparison
CRNX vs FOLD Comparison
Compare CRNX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- FOLD
- Stock Information
- Founded
- CRNX 2008
- FOLD 2002
- Country
- CRNX United States
- FOLD United States
- Employees
- CRNX N/A
- FOLD N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- FOLD Health Care
- Exchange
- CRNX Nasdaq
- FOLD Nasdaq
- Market Cap
- CRNX 2.8B
- FOLD 2.9B
- IPO Year
- CRNX 2018
- FOLD 2007
- Fundamental
- Price
- CRNX $30.16
- FOLD $5.64
- Analyst Decision
- CRNX Strong Buy
- FOLD Buy
- Analyst Count
- CRNX 10
- FOLD 10
- Target Price
- CRNX $75.00
- FOLD $16.22
- AVG Volume (30 Days)
- CRNX 676.7K
- FOLD 4.5M
- Earning Date
- CRNX 08-07-2025
- FOLD 08-07-2025
- Dividend Yield
- CRNX N/A
- FOLD N/A
- EPS Growth
- CRNX N/A
- FOLD N/A
- EPS
- CRNX N/A
- FOLD N/A
- Revenue
- CRNX $760,000.00
- FOLD $543,141,000.00
- Revenue This Year
- CRNX $402.12
- FOLD $19.84
- Revenue Next Year
- CRNX $770.88
- FOLD $23.18
- P/E Ratio
- CRNX N/A
- FOLD N/A
- Revenue Growth
- CRNX N/A
- FOLD 28.25
- 52 Week Low
- CRNX $24.10
- FOLD $5.62
- 52 Week High
- CRNX $62.53
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- CRNX 41.11
- FOLD 33.65
- Support Level
- CRNX $32.05
- FOLD $6.00
- Resistance Level
- CRNX $31.56
- FOLD $6.22
- Average True Range (ATR)
- CRNX 1.08
- FOLD 0.19
- MACD
- CRNX -0.18
- FOLD -0.01
- Stochastic Oscillator
- CRNX 5.25
- FOLD 2.70
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.